GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (STU:4DN) » Definitions » Common Stock

Denali Therapeutics (STU:4DN) Common Stock : €1.6 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Denali Therapeutics Common Stock?

Denali Therapeutics's quarterly common stock declined from Sep. 2023 (€1.6 Mil) to Dec. 2023 (€1.6 Mil) but then increased from Dec. 2023 (€1.6 Mil) to Mar. 2024 (€1.6 Mil).

Denali Therapeutics's annual common stock increased from Dec. 2021 (€1.4 Mil) to Dec. 2022 (€1.6 Mil) but then declined from Dec. 2022 (€1.6 Mil) to Dec. 2023 (€1.6 Mil).


Denali Therapeutics Common Stock Historical Data

The historical data trend for Denali Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Denali Therapeutics Common Stock Chart

Denali Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only 1.16 1.26 1.37 1.59 1.57

Denali Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.58 1.57 1.60 1.57 1.61

Denali Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Denali Therapeutics (STU:4DN) Business Description

Traded in Other Exchanges
Address
161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Denali Therapeutics (STU:4DN) Headlines

No Headlines